Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

Recruiting now

Conditions studied: Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma

In brief

This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS \>1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.

Key facts

Study ID

NCT07448727

Run by

University of Rome Tor Vergata

People needed

25

Starts

2024-11-20

Expected to finish

2027-12-01

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological diagnosis of recurrent and/or metastatic HNSCC, not amenable for curative locoregional treatment (either surgery or radiotherapy), and amenable for first line systemic treatment
• CPS PD-L1 >=1

You may not qualify if…

• Any controindication to immune checkpoint inhibitors

Where it is running

• Tor Vergata University Hospital — Rome, Italy, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.